Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer?

Radiotherapy and Oncology

Volumn 56, Issue 2, 2000, Pages 239-244

  Elsaleh, Hany ^a,b   Robbins, Peter ^c   Joseph, David ^a,b   Powell, Brenda ^b   Grieu, Fabianne ^b   Menso, Lorella ^b   Iacopetta, Barry ^b  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c W Aust Ctr for Pathol Med Res   (Australia)

Author keywords

Chemotherapy; p53; Pre operative; Radiotherapy; Rectal cancer; Tumour response

Indexed keywords

FLUOROURACIL; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RECTUM CANCER; RECURRENCE RISK; SINGLE STRAND CONFORMATION POLYMORPHISM; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034254821     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(00)00184-5     Document Type: Article

References (34)

1. American Joint Committee on Cancer, Manual for staging of cancer, Philadelphia, PA: Lippincott, 1992. pp. 75-84.
2. Adell G., Sun X., Stal O., Klintenberg C., Sjodahl R., Nordenskjold B. p53 status: an indicator for the effect of pre-operative radiotherapy of rectal cancer. Radiother. Oncol. 51:1999;169-174.
3. Baas I.O., van den Berg F.M., Mulder J.W., et al. Potential false-positive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms. J. Pathol. 178:1996;264-267.
4. Bosari S., Viale G. The clinical significance of p53 aberrations in human tumours. Virchows Arch. 427:1995;229-241.
5. Clark A.R., Purdie C.A., Harrison D.J., et al. Thymocyte apoptosis induced by p53-dependent pathways. Nature. 1993;849-852.
6. Desai G.R., Myerson R.J., Higashikubo R., et al. Carcinoma of the rectum. Possible cellular predictors of metastatic potential and response to radiation therapy. Dis. Colon Rectum. 39:1996;1090-1096.
7. Dix B., Robbins P., Carrello S., House A., Iacopetta B. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br. J. Cancer. 70:1994;585-590.
8. Dix B.R., Robbins P.D., Spagnolo D.V., Padovan G.L., House A.K., Iacopetta B.J. Clonal analysis of colorectal tumors using K-ras and p53 gene mutations as markers. Diagn. Mol. Pathol. 4:1995;261-265.
9. Elledge R.M., Gy R., Mansour E., et al. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J. Natl. Cancer Inst. 87:1995;1254-1256.
10. Elsaleh H., Joseph D., Levitt M., et al. Pre-operative chemo-radiotherapy in locally advanced rectal cancer. Is this the way of future management? Aust. Radiol. 43:1999;215-219.
11. Elsaleh H., Joseph D., Levitt M., Robbins P. Pre-operative chemo-radiotherapy in locally advanced cancer. Aust. N. Z. J. Surg. 69:1999;737-742.
12. Fu C.G., Tominaga O., Nagawa H., et al. Role of p53 and p21/WAF1 detection in patient selection for pre-operative radiotherapy in rectal cancer patients. Dis. Colon Rectum. 41:1998;68-74.
13. Ichikawa D., Yamaguchi T., Shirasu M., et al. p53 gene mutation is not directly related to tumoricidal effects of pre-operative radiochemohyperthermia therapy for rectal cancers. J. Surg. Oncol. 63:1996;87-89.
14. Jacquemier J., Penault-Llorca F., Viens P., et al. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. Anticancer Res. 14:1994;2773-2778.
15. Koechli O.R., Schaer G.N., Seifert B. Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet. 344:1994;1647-1648.
16. Lowe S.W., Bodis S., Mcclatchey A., et al. p53 status and the efficacy of cancer therapy in vivo. Science. 266:1994;807-810.
17. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
18. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362:1993;847-849.
19. Makris A., Powles T.J., Dowsett M., Allred C. p53 protein overexpression and chemosensitivity in breast cancer. Lancet. 345:1995;1181-1182.
20. Mathieu M.C., Koscielny S., Le Bihan M.L., Spielmann M., Arriagadan R. p53 protein overexpression and chemosensitivity in breast cancer. Lancet. 345:1995;1182-1182.
21. Minsky B.D., Cohen A.M., Kemeny N., et al. Combined modality therapy of rectal cancer: decreased acute toxicity with the pre-operative approach. J. Clin. Oncol. 10:1992;1218-1224.
22. Minsky B.D., Kemeny N., Cohen A.M., et al. Pre-operative high-dose leucovorin/5-fluorouracil and radiation therapy for unresectable rectal cancer, Cancer. 67:1991;2859-2866.
23. Minsky B.D.C. Treatment systems guidelines for primary rectal cancer from the Patterns of Care Study. Int. J Radiat. Oncol. Biol. Phys. 41:1998;21-27.
24. Moll U.M., Ostermeyer A.G., Ahomadeegbe J.C., Mathieu M.C., Riou G. p53 mediated tumour cell response to chemotherapeutic DNA damage: A preliminary study in matched pairs of breast cancer biopsies. Human Pathol. 26:1995;1293-1301.
25. Moyret C., Theillet C., Laurent-Puig P., Moles J., Thomas G., Hamelin R. Relative efficiency of denaturing gradient gel electrophoresis and single strand conformation polymorphism in the detection of mutations in exons 5 to 8 of the p53 gene. Oncogene. 9:1994;1739-1743.
26. Nehls O., Klump B., Holzmann K., et al. Influence of p53 status on prognosis in pre-operatively irradiated rectal carcinoma. Cancer. 85:1999;2541-2548.
27. Ogawa N., Fujiwara T., Kagawa S., et al. Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. Int. J. Cancer. 73:1997;367-370.
28. Ohue M., Tomita N., Monden T., et al. A frequent alteration of p53 gene in carcinoma in adenoma of colon. Cancer Res. 54:1994;4798-4804.
29. Platell C. A community-based hospital experience with colorectal cancer. Aust. N. Z. J. Surg. 67:1997;420-423.
30. Rich T.A., Skibber J.M., Ajani J.A., et al. Pre-operative infusional chemoradiation therapy for stage T3 rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;1025-1029.
31. Soong R., Grieu F., Robbins P., et al. p53 Alterations are associated with improved prognosis in distal colonic carcinomas. Clin. Cancer Res. 3:1997;1405-1411.
32. Soong R., Iacopetta B.J. A rapid and nonisotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors. Mod. Pathol. 10:1997;252-258.
33. Soong R., Robbins P.D., Dix B.R., et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum. Pathol. 27:1996;1050-1055.
34. Spitz F.R., Giacco G.G., Hess K., et al. p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin. Cancer Res. 3:1997;1685-1690.